US 11390682
Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy
granted A61KA61K2039/505A61K47/6807
Quick answer
US patent 11390682 (Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy) held by Dyne Therapeutics, Inc. expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Dyne Therapeutics, Inc.
- Grant date
- Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2039/505, A61K47/6807, A61K47/6849, A61K47/6889